Market Overview:
The global circulating tumor cells (CTCs) prognostic technologies market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth of the market can be attributed to the increasing incidence of cancer, technological advancements in CTC detection and enrichment techniques, and rising demand for personalized medicine. However, the high cost of diagnosis and treatment may restrain the growth of this market during the forecast period. The tumor cell enrichment segment is expected to dominate the global circulating tumor cells (CTCs) prognostic technologies market during the forecast period owing to technological advancements in this segment that have made it easier and more efficient to detect CTCs. The prostate cancer application segment is expected to account for a major share of this market during the forecast period owing to rising incidence rates globally for this type of cancer.
 Prognostic Technologies Industry Outlook.svg)
Product Definition:
A prognostic technology is a medical test that predicts how likely it is that a person will respond to a particular treatment. Circulating tumor cells (CTCs) are cancer cells that have broken away from the primary tumor site and are circulating in the bloodstream. CTCs can be used to predict how likely it is that a person's cancer will spread, or metastasize, to other parts of the body.
Tumor Cell Enrichment:
Tumor cell enrichment is a process to isolate and concentrate cancer cells from the blood. It's major use is in biopsy specimens for tumor diagnosis. The other important application of tumor cell enrichment is in research settings where it's used to study the behavior and properties of circulating tumor cells (CTCs) that are responsible for metastasis, drug resistance, or recurrence after surgery.
Tumor Cell Detection:
Tumor cell detection and it's usage in circulating tumor cells (CTCs) prognostic technologies market is expected to witness significant growth over the forecast period. Circulating tumor cells (CTCs) are cancerous cells that travel through the blood and infect other organs by entering into another body organ or tissue. CTCs are mostly found in patients with advanced stages of cancer, but sometimes they can also be found in early stage of cancer as well.
Application Insights:
The global market is segmented by application into prostate cancer, breast cancer, colorectal cancer, lung cancer, ovarian cancer and pancreaticcancer. Breastcancer dominated the overall market in terms of revenue in 2017 owing to the increasing prevalence of breast tumor and rising number of research initiatives for early diagnosis methods.
Prostatecancer held a significant share as well due to an increase in incidence rates globally coupled with promising research initiatives for biomarker discovery and development. The Urology Care Foundation has launched a new online tool - MyPCA (mypca.org) that provides information about prostate-specific antigen (PSA) testing benefits along with its limitations along with steps related to PSA testing at home through video tutorials available online & offline across the globe which may further propel growth over next few years.
Regional Analysis:
North America dominated the global CTCs prophylactic technologies market in 2017. This is due to the presence of well-established healthcare infrastructure, high adoption rate of advanced diagnostic techniques and availability of reimbursement facilities for cancer treatment. In addition, government initiatives undertaken to create awareness regarding early diagnosis are expected to fuel regional growth over the forecast period. For instance, in September 2018, The Cancer Genome Atlas (TCGA) program initiated by U.S Department of Health and Human Services (HHS) published a series of research articles that analyzed genomic data from more than 11000 patients with prostate cancer along with their healthy controls [1].
Growth Factors:
- Increasing incidence of cancer: The global incidence of cancer is increasing at an alarming rate. This is expected to drive the demand for CTC prognostic technologies over the forecast period.
- Growing awareness about CTCs: There is a growing awareness among people about the potential benefits of using CTC prognostic technologies for early diagnosis and treatment of cancer. This is likely to boost the demand for these technologies in the coming years.
- Technological advancements: The development of novel and advanced technologies for detection and analysis of CTCs is expected to spur growth in this market over the forecast period.
- Rising funding for research on CTCs: There has been a significant increase in funding by government agencies and private organizations for research on circulating tumor cells in recent years, which is likely to promote growth in this market during the forecast period . 5) Increasing use of personalized medicine: The use if personalized medicine, which involves tailoring treatments according to individual patient characteristics, is increasing rapidly across the world . This trend is expected to benefitthe Circulating Tumor Cells (CTCs) Prognostic Technologies market as well, as thesetechnologies can be usedfor personalizing treatment decisions based onthe presence or absenceofC TCs
Scope Of The Report
Report Attributes
Report Details
Report Title
Circulating Tumor Cells (CTCs) Prognostic Technologies Market Research Report
By Type
Tumor Cell Enrichment, Tumor Cell Detection
By Application
Prostate Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
By Companies
AdnaGen, ACDBio, Celula, Epic Sciences, Fluxion Biosciences, Rarecells, Silicon Biosystems, Vitatex
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Report Segments:
The global Circulating Tumor Cells (CTCs) Prognostic Technologies market is segmented on the basis of:
Types
Tumor Cell Enrichment, Tumor Cell Detection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Prostate Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AdnaGen
- ACDBio
- Celula
- Epic Sciences
- Fluxion Biosciences
- Rarecells
- Silicon Biosystems
- Vitatex
 Prognostic Technologies Market Overview.svg)
Highlights of The Circulating Tumor Cells (CTCs) Prognostic Technologies Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tumor Cell Enrichment
- Tumor Cell Detection
- By Application:
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Circulating Tumor Cells (CTCs) Prognostic Technologies Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Prognostic Technologies Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Circulating tumor cells (CTCs) are a type of cancer cell that is found in the blood and other tissues. CTCs can help doctors predict how likely a person is to develop cancer, and they can also help doctors find and treat cancer early.
Some of the major players in the circulating tumor cells (ctcs) prognostic technologies market are AdnaGen, ACDBio, Celula, Epic Sciences, Fluxion Biosciences, Rarecells, Silicon Biosystems, Vitatex.
The circulating tumor cells (ctcs) prognostic technologies market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Circulating Tumor Cells (CTCs) Prognostic Technologies Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Circulating Tumor Cells (CTCs) Prognostic Technologies Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size & Forecast, 2020-2028
4.5.1 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size and Y-o-Y Growth
4.5.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Tumor Cell Enrichment
5.2.2 Tumor Cell Detection
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Prostate Cancer
6.2.2 Breast Cancer
6.2.3 Colorectal Cancer
6.2.4 Lung Cancer
6.2.5 Ovarian Cancer
6.2.6 Pancreatic Cancer
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Tumor Cell Enrichment
9.6.2 Tumor Cell Detection
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Prostate Cancer
9.10.2 Breast Cancer
9.10.3 Colorectal Cancer
9.10.4 Lung Cancer
9.10.5 Ovarian Cancer
9.10.6 Pancreatic Cancer
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Tumor Cell Enrichment
10.6.2 Tumor Cell Detection
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Prostate Cancer
10.10.2 Breast Cancer
10.10.3 Colorectal Cancer
10.10.4 Lung Cancer
10.10.5 Ovarian Cancer
10.10.6 Pancreatic Cancer
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Tumor Cell Enrichment
11.6.2 Tumor Cell Detection
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Prostate Cancer
11.10.2 Breast Cancer
11.10.3 Colorectal Cancer
11.10.4 Lung Cancer
11.10.5 Ovarian Cancer
11.10.6 Pancreatic Cancer
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Tumor Cell Enrichment
12.6.2 Tumor Cell Detection
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Prostate Cancer
12.10.2 Breast Cancer
12.10.3 Colorectal Cancer
12.10.4 Lung Cancer
12.10.5 Ovarian Cancer
12.10.6 Pancreatic Cancer
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Tumor Cell Enrichment
13.6.2 Tumor Cell Detection
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Prostate Cancer
13.10.2 Breast Cancer
13.10.3 Colorectal Cancer
13.10.4 Lung Cancer
13.10.5 Ovarian Cancer
13.10.6 Pancreatic Cancer
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Circulating Tumor Cells (CTCs) Prognostic Technologies Market: Competitive Dashboard
14.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AdnaGen
14.3.2 ACDBio
14.3.3 Celula
14.3.4 Epic Sciences
14.3.5 Fluxion Biosciences
14.3.6 Rarecells
14.3.7 Silicon Biosystems
14.3.8 Vitatex
